HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 7, July 2016 – Water Technology and Management       » World Toilet Organisation - Let's Talk about Toilets       » Recirculation Aquaculture Systems (RAS): An Opportunity for the SE Asian Aquaculture Industry       » Water Policy Response to Water Scarcity and Future Climate Change Impacts       » Burden of Thrombosis-related Diseases in Asia-Pacific       » Waste Management in Singapore: Where Does Our Rubbish Go?      
INSIDE INDUSTRY
Lantheus Medical Imaging and FUJIFILM RI Pharma renew long-term license and distribution agreement
Lantheus Medical Imaging, Inc., a leader in developing, manufacturing and distributing innovative diagnostic imaging agents, has entered into a new agreement with FUJIFILM RI Pharma Co., Ltd. (FRI) to license and distribute Cardiolite ® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) and Neurolite ® (Kit for the Preparation of Technetium Tc99m Bicisate for Injection) in Japan. Under the terms of the 10-year agreement effective January 1, 2013, which immediately follows an earlier 10-year agreement with FRI, Lantheus will continue to supply FRI with Cardiolite ® and Neurolite ® in finished form as well as provide the raw materials to manufacture and sell the products in unit dose form. Cardiolite ® and Neurolite ® are technetium-based radiopharmaceutical imaging agents used in single-photon emission computed tomography (SPECT).

“We are pleased to continue our long-term collaborative relationship with FRI, which we’ve successfully developed over the past ten years,” said Don Kiepert, President and Chief Executive Officer, Lantheus Medical Imaging.“ Japan represents one of the largest markets for imaging agents worldwide. As such, we share a joint commitment with FRI to provide proven, reliable medical imaging technologies to healthcare providers and patients. This commitment includes ensuring continued access to Cardiolite ® and Neurolite ® for SPECT imaging.”

“Lantheus is the ideal partner for FRI in the Japanese diagnostic imaging market as we have a shared view of the clinical value and benefits of radiopharmaceuticals in the diagnosis of disease,” said Yoshiro Kumano, President and Chief Executive Officer, FRI. “Our customers are our top priority, and we will continue to meet their needs by offering Cardiolite ® and Neurolite ® for use in cardiovascular and brain imaging, respectively.”

Click here for the complete issue.

NEWS CRUNCH  
news Gather China & World Pharmaceutical Entrepreneurs, Create a New Chapter of Chinese Pharma Industry
news Mundipharma's New Betadine® Facility to Meet Regional Healthcare Challenges
news STRATASYS launches World's First Full-ColoUr Multi-material 3D PRINTER - THE J750 - In Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Healthcare Technology Outlook 2020 - Technology uptake
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com or Mr Edward
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy